Evaluation of the Preventive Effect of Photobiomodulation on Orofacial Discomfort in Dental Procedures: A Randomized-Controlled, Crossover Study and Clinical Trial.

Background: Orofacial pain has been a prevalent symptom in the worldwide population, which may cause restrictions in daily activities and, consequently, have a great impact on the well-being of affected individuals. Photobiomodulation using light sources, such as low-level laser or light emitting diodes, with different wavelengths, has been widely used in the last years, in addition to being a noninvasive, low-cost resource and reducing pain. Objective: This study aimed at evaluating the effect of photobiomodulation as a protocol treatment to prevent facial muscle discomfort after long-term clinical procedures. Methods: The volunteers were randomized and allocated as follows: laser (n = 16) and placebo (n = 16) groups, following a crossover study design. The laser parameters were as following: 786 nm wavelength, 9 J per point, and 100 mW power of 2.393 W/cm2 irradiance. The discomfort was induced by simulating a 50-min dental procedure (with bilateral mouth open), and the pain scale (assessed bilaterally), tiredness, and temperature measurement through thermography were used for analysis. Results: The results showed a significant lower pain and tiredness in the laser group. Also, the results showed a statistically significant valid temperature change between the groups at times: T1, T40, and T50. Conclusions: According to our results, photobiomodulation showed a positive effect on the face musculature in patients submitted to the treatments, reducing pain and improving the subjective perception of exertion.

Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis - Randomized clinical trial.

OBJECTIVE: Investigate the effects of photobiomodulation (PBM) on the expression of IL-10 and nitrites in individuals with Relapsing-Remitting multiple sclerosis (MS), as these biomarkers play a fundamental role in the physiopathology of the disease. The modulation of IL-10 and nitrites through treatment with PBM may be a novel treatment modality for MS. METHODS: A randomized, uncontrolled, clinical trial was conducted involving 14 individuals with a diagnosis of Relapsing-Remitting MS and a score of up to 6.0 on the Expanded Disability Status Scale (EDSS). THE PARTICIPANTS WERE RANDOMIZED TO TWO GROUPS: Group 1 -PBM in the sublingual region; Group 2 -PBM over the radial artery. Irradiation was administered with a wavelength of 808 nm and output power of 100 mW for 360 seconds twice a week, totaling 24 sessions. Peripheral blood was analyzed for the determination of serum levels of IL-10 and nitrites. RESULTS: After treatment with PBM, the expression of IL-10 increased in both the sublingual group (pre-treatment: 2.8 ± 1.4 pg/ml; post-treatment: 8.3 ± 2.4 pg/ml) and the radial artery group (pre-treatment: 2.7 pg/ml ± 1.4; post-treatment: 11.7 ± 3.8 pg/ml). In contrast, nitrite levels were not modulated in the sublingual group (pre-treatment: 65 ± 50 nmol/mg protein; post-treatment: 51 ± 42 nmol/mg protein) or the radial artery group (pre-treatment: 51 ± 16 nmol/mg protein; post-treatment: 42 ± 7 nmol/mg protein). CONCLUSION: Treatment with PBM positively modulated the expression of IL-10 but had no effect on nitrite levels. Further studies should be conducted with a larger sample and a control group, as PBM may be a promising complementary treatment for the management of MS. This trial is registered at ClinicalTrials.gov. Identifier: NCT03360487.